Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura

被引:64
|
作者
Uchida, T
Wada, H
Mizutani, M
Iwashita, M
Ishihara, H
Shibano, T
Suzuki, M
Matsubara, Y
Soejima, K
Matsumoto, M
Fujimura, Y
Ikeda, Y
Murata, M
机构
[1] Keio Univ, Dept Med, Shinjuku Ku, Tokyo, Japan
[2] Daichi Pharmaceut, New Prod Res Labs 2, Tokyo, Japan
[3] Mie Univ, Sch Med, Dept Lab Med, Tsu, Mie, Japan
[4] Chemo Sero Therapeut Res Inst, Res Dept 1, Kumamoto, Japan
[5] Nara Med Univ, Dept Blood Transfus, Kashihara, Nara, Japan
关键词
D O I
10.1182/blood-2004-02-0715
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Congenital thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) is associated with an inherited von Willebrand factor-cleaving protease (ADAMTS13 [a disintegrin and metalloprotease with thrombospondin type I domains 13]) deficiency. In this study, we identified novel mutations in the ADAMTS13 gene in a patient with TTP. The patient was a 51-year-old Japanese male who exhibited TTP symptoms at frequent intervals. The ADAMTS13 activity during acute episodes was less than 3% that of normal. The enzyme activities of the patient's father and mother were both 46%, and both parents were asymptomatic. Genetic analysis revealed that the patient was a compound heterozygote for 2 mutations. One mutation was a missense mutation in the metalloprotease domain (A250V, exon 7), and the other was a guanine to adenine substitu- tion at the 5' end of intron 3 (intron 3 G A). In vitro expression studies revealed that the A250V mutation markedly reduced ADAMTS13 activity and the intron 3 G-->A mutation caused abnormal mRNA synthesis. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:2081 / 2083
页数:3
相关论文
共 50 条
  • [41] VALIDATION OF A NOVEL ADAMTS13 ASSAY FOR CHARACTERIZATION OF PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA
    Barton, J. Cameron
    Miranda, Frida
    Anderson, Cooper
    Muia, Joshua
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E9 - E10
  • [42] Proteolysis of ADAMTS13 in acute phase thrombotic thrombocytopenic purpura
    Feys, H. B.
    Vandeputte, N.
    Peerlinck, K.
    Peyvandi, F.
    Vanhoorelbeke, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 655 - 655
  • [43] Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13
    Pimanda, JE
    Maekawa, A
    Wind, T
    Paxton, J
    Chesterman, CN
    Hogg, PJ
    BLOOD, 2004, 103 (02) : 627 - 629
  • [44] ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura
    Zheng, X. Long
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 211 - 225
  • [45] Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond
    Lian, ECY
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (06): : 625 - 632
  • [46] Diagnosis of Thrombotic Thrombocytopenic Purpura by ADAMTS13 Activity Quantification
    Dimopoulos, Konstantinos
    Philips, Malou
    Goetze, Jens P.
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2022, 7 (03): : 637 - 649
  • [47] Utility of ADAMTS13 Assays in Diagnosing Thrombotic Thrombocytopenic Purpura
    Lehman, Christopher M.
    Rodgers, George M.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (04) : 433 - 433
  • [48] Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura
    Minola Manea
    Diana Karpman
    Pediatric Nephrology, 2009, 24 : 447 - 458
  • [49] Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
    Sadler, J. Evan
    BLOOD, 2008, 112 (01) : 11 - 18
  • [50] ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura
    Sui, Jingrui
    Zheng, Liang
    Zheng, X. Long
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2023, 147 (08) : 974 - 979